Deep Pharma Intelligence announces the release of a new, open-access 130-page analytical report and interactive analytics Dashboard: AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2020. This delivers advanced market intelligence, interactive mindmaps, benchmarking for companies, investors and technologies, competitive and SWOT analysis through the interactive IT-Platform and Big Data analytical Dashboard. The current release includes insights about 240+ biotech companies, 600+ investors, 90+ pharma corporations, and 35 R&D centres in the area of pharmaceutical and healthcare artificial intelligence (AI).
Based on the analysis of the key players and overall industry dynamics, our team identified a number of key trends and insights about the investment landscape, R&D collaborations, AI application use cases, and more. Some of the key takeaways include the following conclusions:
- The segment of pharmaceutical AI continues consolidation;
- Pharmaceutical AI sector is “heating up” for investments;
- Big pharma and contract research organizations increasingly compete for AI partnerships;
- The sector of pharmaceutical AI is maturing for a likely wave of IPOs and M&As in 2021-2022;
- COVID-19 pandemics appears to be a positive catalyst for the acceleration of the AI adoption
The report and the analytics dashboard are tools for strategic insights, opportunity evaluation, competitor profiling, and other goals, relevant to pharma and biotech decision makers, life science investors, consulting companies, and regulatory agencies.
The 130-page open-access report and the underlying IT-platform marks the 9th instalment in a series of reports on the topic of the artificial Intelligence application in pharmaceutical research that Deep Pharma Intelligence has been producing since 2017. The central aim of this series of special case studies is to provide a comprehensive overview of the industry landscape and try to predict what is coming next.
The report Artificial intelligence (AI) for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2020 and the underlying IT-platform and analytics dashboard mark the inaugural project of Deep Pharma Intelligence, a new joint venture of Deep Knowledge Analytics Pharma Division and BPT Analytics (BiopharmaTrend).